GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (LTS:0QXX) » Definitions » Price-to-Funds-From-Operations

Molecular Partners AG (LTS:0QXX) Price-to-Funds-From-Operations : (As of Dec. 15, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Molecular Partners AG Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.